 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- | itacitinib (INCB039110) / Incyte
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Sep 14, 2018
P3, N=266, Not yet recruiting, Sponsor: Incyte Corporation
Trial completion date: Dec 2021 --> Oct 2023 | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: Jun 2021 --> Aug 2023
- | Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Trial completion: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=166, Completed, Sponsor: Children's Oncology Group
Trial completion date: Dec 2021 --> Oct 2023 | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: Jun 2021 --> Aug 2023 Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Metastases: c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jul 30, 2018
P1/2, N=39, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Trial completion date: Jan 2020 --> Aug 2025
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial primary completion date: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jul 24, 2018
P3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2020 --> Aug 2025 Trial primary completion date: Nov 2019 --> Dec 2020
- ||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open, Enrollment change: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 24, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2019 --> Dec 2020 Active, not recruiting --> Recruiting | N=20 --> 60
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion, Trial completion date, Trial primary completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2018
P3, N=218, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting | N=20 --> 60 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017
- | itacitinib (INCB039110) / Incyte
New P3 trial, Combination therapy: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Jul 11, 2018
P3, N=266, Not yet recruiting, Sponsor: Incyte Corporation
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 26, 2018
P3, N=509, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017 N=360 --> 509
- || prednisone delayed-release tablet / Generic mfg.
Trial completion date, Trial primary completion date: RIFLE: A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (clinicaltrials.gov) - Jun 21, 2018
P4, N=62, Recruiting, Sponsor: Ampel BioSolutions, LLC
N=360 --> 509 Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Sep 2018
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 15, 2018
P3, N=1895, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Completed
- || Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial completion date, Trial primary completion date, Combination therapy: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Mar 22, 2018
P2, N=200, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020
- || Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial completion date: NCI-2018-01064: Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer (clinicaltrials.gov) - Mar 20, 2018
P2, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020 Trial completion date: Oct 2021 --> Oct 2022
- |||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Enrollment open, Trial initiation date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 8, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2021 --> Oct 2022 Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Mar 2018
- | veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial completion date, Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 5, 2018
P2, N=148, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial initiation date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 12, 2018
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Mar 2018 Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Oct 2018 --> Oct 2019 | Trial completion date: Oct 2018 --> Oct 2020
- | Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jan 19, 2018
P2, N=345, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Oct 2018 --> Oct 2019 | Trial completion date: Oct 2018 --> Oct 2020 Trial primary completion date: Jan 2018 --> Aug 2019
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Metastases: c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jan 18, 2018
P1/2, N=39, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jan 2018 --> Aug 2019 Trial primary completion date: Jun 2018 --> Jan 2019
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P2, N=0, Completed, Sponsor: University of Nebraska
Trial primary completion date: Jun 2018 --> Jan 2019 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion: Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 16, 2018
P3, N=0, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Enrollment open: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Jan 8, 2018
P3, N=5956, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Dec 12, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: Aug 2013 --> Sep 2017
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Dec 12, 2017
P2, N=40, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Aug 2013 --> Sep 2017 Trial primary completion date: May 2019 --> Dec 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 8, 2017
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2019 --> Dec 2019 Trial primary completion date: Jun 2018 --> Jun 2021
- alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 5, 2017
P1/2, N=9, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial primary completion date: Jun 2018 --> Jun 2021 Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Mar 2015
- | abiraterone acetate / Generic mfg.
Biomarker, Enrollment closed, Trial initiation date, IO biomarker: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Dec 5, 2017
P3, N=600, Active, not recruiting, Sponsor: Han Xu, M.D., Ph.D., Sponsor-Investigator-Monitor, IRB Chair
Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Mar 2015 Not yet recruiting --> Active, not recruiting | Initiation date: Apr 2018 --> Nov 2017
- ||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, New P2 trial, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Dec 4, 2017
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | abiraterone acetate / Generic mfg.
Biomarker, New P3 trial, IO biomarker: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Nov 21, 2017
P3, N=600, Not yet recruiting, Sponsor: Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Nov 17, 2017
P1, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting | Initiation date: Apr 2018 --> Nov 2017 Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Sep 2020
- |||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Enrollment open, Trial initiation date, Trial primary completion date: NCI-2018-01064: Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer (clinicaltrials.gov) - Oct 18, 2017
P2, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Sep 2020 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Oct 2017 | Trial primary completion date: Feb 2022 --> Oct 2021
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 16, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Oct 2017 | Trial primary completion date: Feb 2022 --> Oct 2021 Trial primary completion date: Sep 2017 --> Aug 2013
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, IO biomarker: Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) (clinicaltrials.gov) - Oct 10, 2017
P2, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2017 --> Aug 2013 Trial primary completion date: Jan 2018 --> Jan 2019
- ||| prednisone delayed-release tablet / Generic mfg.
Trial initiation date, Trial primary completion date: RIFLE: A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (clinicaltrials.gov) - Sep 27, 2017
P4, N=62, Recruiting, Sponsor: Ampel BioSolutions, LLC
Trial primary completion date: Jan 2018 --> Jan 2019 Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Mar 2018 --> Jun 2018
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial suspension: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Sep 12, 2017
P3, N=5437, Suspended, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Mar 2018 --> Jun 2018 Recruiting --> Suspended
- ||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
New P2 trial: NCI-2018-01064: Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer (clinicaltrials.gov) - Sep 12, 2017
P2, N=66, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Clinical: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Sep 1, 2017
P2, N=150, Recruiting, Sponsor: National Cancer Institute (NCI)
- |||| nelarabine / Generic mfg.
Enrollment open: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 18, 2017
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Active, not recruiting --> Recruiting
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial initiation date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Aug 17, 2017
P2, N=44, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting Initiation date: May 2017 --> Dec 2017
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Aug 8, 2017
P2, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2017 --> Dec 2017 Trial primary completion date: Jul 2017 --> Oct 2016
- ||| nelarabine / Generic mfg.
Enrollment closed: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jul 21, 2017
P2, N=84, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Oct 2016 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Jul 18, 2017
P1, N=54, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||||| itacitinib (INCB039110) / Incyte
Combination therapy: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Jun 22, 2017
P3, N=436, Recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| prednisone delayed-release tablet / Generic mfg.
Trial initiation date: RIFLE: A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (clinicaltrials.gov) - Jun 8, 2017
P4, N=62, Recruiting, Sponsor: Ampel BioSolutions, LLC
Not yet recruiting --> Recruiting Initiation date: Mar 2017 --> Jun 2017
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - May 31, 2017
P2, N=44, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- |||||||||| itacitinib (INCB039110) / Incyte
Combination therapy: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - May 4, 2017
P3, N=436, Not yet recruiting, Sponsor: Incyte Corporation
- prednisone delayed-release tablet / Generic mfg.
Phase classification, Enrollment change, Trial termination: Delayed Release Prednisone in PMR (clinicaltrials.gov) - May 3, 2017
P2, N=8, Terminated, Sponsor: Dinora, Inc.
Not yet recruiting --> Recruiting Phase classification: P4 --> P2 | N=45 --> 8 | Recruiting --> Terminated; lack of study recruitment
- | veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 25, 2017
P2, N=148, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P4 --> P2 | N=45 --> 8 | Recruiting --> Terminated; lack of study recruitment Trial primary completion date: Dec 2016 --> Dec 2017
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Apr 13, 2017
P2, N=44, Not yet recruiting, Sponsor: City of Hope Medical Center
- ||||| prednisone delayed-release tablet / Generic mfg.
New P4 trial: RIFLE: A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (clinicaltrials.gov) - Apr 4, 2017
P4, N=62, Recruiting, Sponsor: Ampel BioSolutions, LLC
- | Trial completion: Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 6, 2017
P2, N=76, Completed, Sponsor: Stanford University
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- || nelarabine / Generic mfg.
Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 17, 2017
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Jul 2019